Hemoperfusion with HA380 in acute type A aortic dissection patients undergoing aortic arch operation (HPAO): a randomized, controlled, double-blind clinical trial

Jing Yang, Dong Ji, Yue-Qian Zhu, Yun Ren, Xun Zhang, Hong-Yu Dai, Xu Sun, Yi Zhou, Zhi-Yuan Chen, Qing-Guo Li, Hao Yao, Jing Yang, Dong Ji, Yue-Qian Zhu, Yun Ren, Xun Zhang, Hong-Yu Dai, Xu Sun, Yi Zhou, Zhi-Yuan Chen, Qing-Guo Li, Hao Yao

Abstract

Background: Cardiopulmonary bypass (CPB) is an important cause of significant systemic inflammatory response syndrome (SIRS) in the surgical treatment of acute type A aortic dissection (ATAAD). In patients with arch vessel involvement, extensive surgical repairs often necessitate prolonged use of CPB and results in extensive inflammatory responses. Cytokines and chemokines released during CPB contribute to the progression of SIRS, increase perioperative complications, and negatively impact surgical outcomes. A cytokine adsorber (HA380) is expected to reduce the level of cytokines during CPB, which may decrease both intraoperative and postoperative inflammation. The purpose of this study is to investigate if HA380 is able to reduce the levels of inflammatory cytokines and decrease perioperative complications in ATAAD patients undergoing CPB and deep hypothermic circulatory arrest (DHCA).

Methods: This study is a single-center, randomized, controlled, double-blind clinical trial. The study aims to recruit 88 patients with ATAAD and aortic arch involvement who will undergo CPB and DHCA to repair the dissected aorta. Patients will be randomized equally into the CPB/DHCA only group (control group) and the CPB/DHCA + HA380 hemoperfusion group (intervention group), with 44 patients each. Patients in the control group will undergo CPB and DHCA only, while patients in the intervention group will undergo continuous hemoperfusion with HA380, in addition to CPB and DHCA. The primary outcome is a composite of major perioperative complications. The secondary outcomes include related inflammatory markers, coagulation parameters, and minor perioperative complications. To comprehensively evaluate the effect of hemoperfusion on the perioperative outcomes, we will also determine if there are differences in perioperative all-cause mortality, length of ICU stay, and total hospitalization costs.

Discussion: In the current trial, hemoperfusion will be applied in patients undergoing CPB and DHCA for repair of the aorta involving the aortic arch. This trial aims to test the safety and efficacy of our hemoperfusion device (HA380) in such settings. Upon completion of the trial, we will determine if HA380 is effective in reducing perioperative proinflammatory cytokine levels. Further, we will also verify if reduction in the proinflammatory cytokine levels, if present, translates to improvement in patient outcomes.

Trial registration: ClinicalTrials.gov NCT04007484 . Registered on 1 July 2019 (retrospectively registered).

Keywords: Acute type A aortic dissection; Cardiopulmonary bypass; Coagulation indicators; Deep hypothermic circulatory arrest; HA380; Inflammatory factors.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the hemoperfusion in acute type A aortic dissection patients undergoing aortic arch operation (HPAO) trial
Fig. 2
Fig. 2
HA380 hemoperfutor setup in the CPB circuit. Venous blood first enters the venous reservoir, where it subsequently flows into the oxygenator with a driving force from a roller pump. After oxygenation, the majority of the oxygenated blood goes into the arterial circulation for perfusion, roughly 700 ml/min (14–18%) goes through the hemoperfusion device HA380 for hemofiltration. The filtered blood then returns to the venous reservoir and mixes with the venous blood. No other additional equipment is required
Fig. 3
Fig. 3
Schedule of enrollment, intervention, perioperative data, and laboratory parameters at different time points on the basis of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement. T0, before operation; T1, CPB initiation; T2, lowest intraoperative temperature; T3, end of CPB; T4, end of the operation; T5, 24 h after completion of the procedure; T6, 48 h after completion of the procedure; T7, 72 h after completion of the procedure; CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; MIF, macrophage migration inhibitory factor; PO 3M, postoperative 3 months; PO 6M, postoperative 6 months

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
    1. Delannoy B, Guye ML, Slaiman DH, Lehot JJ, Cannesson M. Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations. Crit Care. 2009;13(6):R180. doi: 10.1186/cc8166.
    1. Hensel M, Volk T, Docke WD, Kern F, Tschirna D, Egerer K, Konertz W, Kox WJ. Hyperprocalcitonemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anesthesiology. 1998;89(1):93–104. doi: 10.1097/00000542-199807000-00016.
    1. Salameh A, Dhein S. Strategies for pharmacological organoprotection during extracorporeal circulation targeting ischemia-reperfusion injury. Front Pharmacol. 2015;6:296. doi: 10.3389/fphar.2015.00296.
    1. Sugita J, Fujiu K. Systemic inflammatory stress response during cardiac surgery. Int Heart J. 2018;59(3):457–459. doi: 10.1536/ihj.18-210.
    1. Baumann A, Buchwald D, Annecke T, Hellmich M, Zahn PK, Hohn A. RECCAS - REmoval of cytokines during CArdiac surgery: study protocol for a randomised controlled trial. Trials. 2016;17(1):137. doi: 10.1186/s13063-016-1265-9.
    1. McGuinness J, Bouchier-Hayes D, Redmond JM. Understanding the inflammatory response to cardiac surgery. Surgeon. 2008;6(3):162–171. doi: 10.1016/S1479-666X(08)80113-8.
    1. Squiccimarro E, Labriola C, Malvindi PG, Margari V, Guida P, Visicchio G, Kounakis G, Favale A, Dambruoso P, Mastrototaro G, et al. Prevalence and clinical impact of systemic inflammatory reaction after cardiac surgery. J Cardiothorac Vasc Anesth. 2019;33(6):1682–1690. doi: 10.1053/j.jvca.2019.01.043.
    1. Allan CK, Newburger JW, McGrath E, Elder J, Psoinos C, Laussen PC, del Nido PJ, Wypij D, McGowan FX., Jr The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010;111(5):1244–1251. doi: 10.1213/ANE.0b013e3181f333aa.
    1. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10000):1243–1253. doi: 10.1016/S0140-6736(15)00273-1.
    1. Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: a case study. Indian J Crit Care Med. 2014;18(12):822–824. doi: 10.4103/0972-5229.146321.
    1. Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, Lamm C, Preissing F, Wiedemann D, Hiesmayr MJ, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016;20:96. doi: 10.1186/s13054-016-1270-0.
    1. Futier E, Biais M, Godet T, Bernard L, Rolhion C, Bourdier J, Morand D, Pereira B, Jaber S, Committee FTM Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH trial): study protocol for a randomized controlled trial. Trials. 2015;16:582. doi: 10.1186/s13063-015-1085-3.
    1. Callum J, Farkouh ME, Scales DC, Heddle NM, Crowther M, Rao V, Hucke HP, Carroll J, Grewal D, Brar S, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial. JAMA. 2019;322(20):1–11. doi: 10.1001/jama.2019.17312.
    1. Poli EC, Alberio L, Bauer-Doerries A, Marcucci C, Roumy A, Kirsch M, De Stefano E, Liaudet L, Schneider AG. Cytokine clearance with CytoSorb(R) during cardiac surgery: a pilot randomized controlled trial. Crit Care. 2019;23(1):108. doi: 10.1186/s13054-019-2399-4.
    1. Pomare Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood Hemoperfusion. Blood Purif. 2018;46(3):187–195. doi: 10.1159/000489921.
    1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184.
    1. Hogue CW, Jr, Sundt T, 3rd, Barzilai B, Schecthman KB, Davila-Roman VG. Cardiac and neurologic complications identify risks for mortality for both men and women undergoing coronary artery bypass graft surgery. Anesthesiology. 2001;95(5):1074–1078. doi: 10.1097/00000542-200111000-00008.
    1. Hessel EA., 2nd Abdominal organ injury after cardiac surgery. Semin Cardiothorac Vasc Anesth. 2004;8(3):243–263. doi: 10.1177/108925320400800306.
    1. Raman JS, Kochi K, Morimatsu H, Buxton B, Bellomo R. Severe ischemic early liver injury after cardiac surgery. Ann Thorac Surg. 2002;74(5):1601–1606. doi: 10.1016/S0003-4975(02)03877-8.
    1. Subramaniam B, Shankar P, Shaefi S, Mueller A, O'Gara B, Banner-Goodspeed V, Gallagher J, Gasangwa D, Patxot M, Packiasabapathy S, et al. Effect of intravenous acetaminophen vs placebo combined with propofol or dexmedetomidine on postoperative delirium among older patients following cardiac surgery: the DEXACET randomized clinical trial. JAMA. 2019;321(7):686–696. doi: 10.1001/jama.2019.0234.
    1. Almdahl SM, Rynning SE, Veel T, Halvorsen P, Molstad P. Postoperatively increased serum alanine aminotransferase level is closely associated with mortality after cardiac surgery. Thorac Cardiovasc Surg. 2015;63(1):67–72.
    1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Executive Group on behalf of the Joint European Society of Cardiology /American College of Cardiology /American Heart Association /World Heart Federation Task Force for the Universal Definition of Myocardial I: Fourth Universal Definition of Myocardial Infarction (2018) Circulation. 2018;138(20):e618–e651. doi: 10.1161/CIR.0000000000000617.
    1. Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review. Blood Purif. 2018;46(4):337–349. doi: 10.1159/000492379.
    1. Trager K, Fritzler D, Fischer G, Schroder J, Skrabal C, Liebold A, Reinelt H. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs. 2016;39(3):141–146. doi: 10.5301/ijao.5000492.
    1. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(Suppl 1):S34–S45. doi: 10.1002/eji.200737772.
    1. Nebelsiek T, Beiras-Fernandez A, Kilger E, Mohnle P, Weis F. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. Recent Pat Cardiovasc Drug Discov. 2012;7(3):170–174. doi: 10.2174/157489012803832829.
    1. Andersson U, Tracey KJ. Reflex principles of immunological homeostasis. Annu Rev Immunol. 2012;30:313–335. doi: 10.1146/annurev-immunol-020711-075015.
    1. Gerlach H. Agents to reduce cytokine storm. F1000Res. 2016;5:2909. doi: 10.12688/f1000research.9092.1.
    1. Datzmann T, Trager K. Extracorporeal membrane oxygenation and cytokine adsorption. J Thorac Dis. 2018;10(Suppl 5):S653–S660. doi: 10.21037/jtd.2017.10.128.
    1. Matsuda K, Moriguchi T, Harii N, Goto J. Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfus Apher Sci. 2009;40(1):49–53. doi: 10.1016/j.transci.2008.11.003.
    1. Hosgood SA, Moore T, Kleverlaan T, Adams T, Nicholson ML. Haemoadsorption reduces the inflammatory response and improves blood flow during ex vivo renal perfusion in an experimental model. J Transl Med. 2017;15(1):216. doi: 10.1186/s12967-017-1314-5.
    1. Franke A, Lante W, Fackeldey V, Becker HP, Thode C, Kuhlmann WD, Markewitz A. Proinflammatory and antiinflammatory cytokines after cardiac operation: different cellular sources at different times. Ann Thorac Surg. 2002;74(2):363–370. doi: 10.1016/S0003-4975(02)03658-5.
    1. Allen ML, Hoschtitzky JA, Peters MJ, Elliott M, Goldman A, James I, Klein NJ. Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. Crit Care Med. 2006;34(10):2658–2665. doi: 10.1097/01.CCM.0000240243.28129.36.
    1. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3(10):791–800. doi: 10.1038/nri1200.
    1. Leyton-Jaimes MF, Kahn J, Israelson A. Macrophage migration inhibitory factor: a multifaceted cytokine implicated in multiple neurological diseases. Exp Neurol. 2018;301(Pt B):83–91. doi: 10.1016/j.expneurol.2017.06.021.
    1. Stoppe C, Averdunk L, Goetzenich A, Soppert J, Marlier A, Kraemer S, Vieten J, Coburn M, Kowark A, Kim BS, et al. The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery. Sci Transl Med. 2018;10(441):eaan4886. doi: 10.1126/scitranslmed.aan4886.
    1. Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm. J Extra Corpor Technol. 2008;40(4):257–267.
    1. Murphy GS, Whitlock RP, Gutsche JT, Augoustides JG. Steroids for adult cardiac surgery with cardiopulmonary bypass: update on dose and key randomized trials. J Cardiothorac Vasc Anesth. 2013;27(5):1053–1059. doi: 10.1053/j.jvca.2013.04.022.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する